The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Safety of Recombinant Activated Factor VII in Randomized Clinical Trials
Open accessAbstract
BACKGROUND: The use of recombinant activated factor VII (rFVIIa) on an off-label basis to treat life-threatening bleeding has been associated with a perceived increased risk of thromboembolic complications. However, data from placebo-controlled trials are needed to properly assess the thromboembolic risk. To address this issue, we evaluated the rate of thromboembolic events in all published randomized, placebo-controlled trials of rFVIIa used on an off-label basis. METHODS: We analyzed data from 35 randomized clinical trials (26 studies involving patients and 9 studies involving healthy volunteers) to determine the frequency of thromboembolic events. The data were pooled with the use of random-effects models to calculate the odds ratios and 95% confidence intervals. RESULTS: Among 4468 subjects (4119 patients and 349 healthy volunteers), 401 [corrected] had thromboembolic events (9.0%). [corrected] Rates of arterial thromboembolic events among all 4468 subjects were higher among those who received rFVIIa than among those who received placebo (5.5% vs. 3.2%, P=0.003). Rates of venous thromboembolic events were similar among subjects who received rFVIIa and those who received placebo (5.3% vs. 5.7%). Among subjects who received rFVIIa, 2.9% had coronary arterial thromboembolic events, as compared with 1.1% of those who received placebo (P=0.002). Rates of arterial thromboembolic events were higher among subjects who received rFVIIa than among subjects who received placebo, particularly among those who were 65 years of age or older (9.0% vs. 3.8%, P=0.003); the rates were especially high among subjects 75 years of age or older (10.8% vs. 4.1%, P=0.02). CONCLUSIONS: In a large and comprehensive cohort of persons in placebo-controlled trials of rFVIIa, treatment with high doses of rFVIIa on an off-label basis significantly increased the risk of arterial but not venous thromboembolic events, especially among the elderly. (Funded by Novo Nordisk.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murphy, G. J., Reeves, B. C., Rogers, C. A., Rizvi, S. I. A., Culliford, L., & Angelini, G. D. (2007) · Circulation · doi:10.1161/circulationaha.107.698977 · Cited by 1,371
Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707534 · Cited by 1,255
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042991 · Cited by 1,167
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Mayer, S. A. (2007) · Stroke · doi:10.1161/01.str.0000254499.46122.22 · Cited by 1,034
Boffard, K. D., Riou, B., Warren, B., Choong, P. I. T., Rizoli, S., Rossaint, R., Axelsen, M., & Kluger, Y. (2005) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/01.ta.0000171453.37949.b7 · Cited by 780
Samama, M.-M. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.22.3415 · Cited by 695
Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa
O’Connell, K. A. (2006) · JAMA · doi:10.1001/jama.295.3.293 · Cited by 671
Venous thromboembolism: disease burden, outcomes and risk factors
HEIT, J. A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01415.x · Cited by 447
Bosch, J., Thabut, D., Bendtsen, F., D’Amico, G., Albillos, A., González Abraldes, J., Fabricius, S., Erhardtsen, E., & de Franchis, R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.015 · Cited by 401
Risk Factors for Venous Thrombotic Disease
Rosendaal, F. R. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615887 · Cited by 375
Cited by
Rossaint, R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1265-x · Cited by 1,484
Spahn, D. R., Bouillon, B., Cerny, V., Duranteau, J., Filipescu, D., Hunt, B. J., Komadina, R., Maegele, M., Nardi, G., Riddez, L., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2347-3 · Cited by 1,269
Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
Rossaint, R., Afshari, A., Bouillon, B., Cerny, V., Cimpoesu, D., Curry, N., Duranteau, J., Filipescu, D., Grottke, O., Grønlykke, L., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04327-7 · Cited by 776
Prevention and Management of Postpartum Haemorrhage: Green‐top Guideline No. 52
(2017) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.14178 · Cited by 756
Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.015 · Cited by 645
Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding
Hickman, D. A., Pawlowski, C. L., Sekhon, U. D. S., Marks, J., & Gupta, A. S. (2018) · Advanced Materials · doi:10.1002/adma.201700859 · Cited by 583
Cannon, J. W., Khan, M. A., Raja, A. S., Cohen, M. J., Como, J. J., Cotton, B. A., Dubose, J. J., Fox, E. E., Inaba, K., Rodriguez, C. J., et al. (2017) · Journal of Trauma and Acute Care Surgery · doi:10.1097/ta.0000000000001333 · Cited by 481
Bolliger, D., Seeberger, M. D., & Tanaka, K. A. (2012) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2011.07.005 · Cited by 397
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
Kaatz, S., Kouides, P. A., Garcia, D. A., Spyropolous, A. C., Crowther, M., Douketis, J. D., Chan, A. K. C., James, A., Moll, S., Ortel, T. L., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23202 · Cited by 365
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1310-7 · Cited by 333
Bleeding and Coagulopathies in Critical Care
Hunt, B. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1208626 · Cited by 324
Marchesi, C., Pierfranceschi, M., Crowther, M., Garcia, D., Hylek, E., Witt, D., Clark, N., Squizzato, A., Imberti, D., Ageno, W., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-01-0052 · Cited by 306
Ferraris, V. A., Saha, S. P., Oestreich, J. H., Song, H. K., Rosengart, T., Reece, T. B., Mazer, C. D., Bridges, C. R., Despotis, G. J., Jointer, K., et al. (2012) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2012.07.086 · Cited by 293
Association of Off-label Drug Use and Adverse Drug Events in an Adult Population
Eguale, T., Buckeridge, D. L., Verma, A., Winslade, N. E., Benedetti, A., Hanley, J. A., & Tamblyn, R. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.6058 · Cited by 262
Alternatives to blood transfusion
Spahn, D. R., & Goodnough, L. T. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60808-9 · Cited by 261
Off-Label Use vs Off-Label Marketing of Drugs
Van Norman, G. A. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2022.12.011 · Cited by 49
Metadata
- Authors
- Levi, M., Levy, J. H., Andersen, H. F., & Truloff, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-11-04
- Volume
- 363
- Issue
- 19
- Pages
- 1791-1800
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2355654874
- Cited by
- 677
- References
- 25
- FWCI
- 46.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.